When was Viridian Therapeutics founded?

Viridian Therapeutics was founded in 2007 and raised its 1st funding round 3 years after it was founded.

Where is Viridian Therapeutics located?

Viridian Therapeutics is headquartered in Boulder, United States. It is registered at Waltham,Massachusetts.

How many employees does Viridian Therapeutics have?

As of Aug 31, 2026, the latest employee count at Viridian Therapeutics is 415.

Is Viridian Therapeutics a funded company?

Viridian Therapeutics is a funded company, having raised a total of $14.5M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 10, 2010.

When was the latest funding round of Viridian Therapeutics?

Viridian Therapeutics' latest funding was a $***** Post IPO round on May 11, 2026, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.27B in funding in 2026 to date.

What is the annual revenue of Viridian Therapeutics?

Annual revenue of Viridian Therapeutics is between $50M and $100M as on Dec 31, 2025

Where does Viridian Therapeutics rank among its competitors?

Viridian Therapeutics ranks 17th amongst 2925 active competitors, of which 994 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Viridian Therapeutics?

Viridian Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Viridian Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Viridian Therapeutics is a public company based in Boulder (United States), founded in 2007 by Vahe Bedian. It operates as a Developer of medicines for patients with serious and rare diseases. Viridian Therapeutics has raised $14.5M in funding. The company has 2925 active competitors, including 994 funded and 723 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of medicines for patients with serious and rare diseases. The company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Website: viridiantherapeutics.com
Social
Email ID: *****@viridiantherapeutics.com
Phone Number: +1 **********
Part Of
Registered Address: Waltham,Massachusetts

Key Metrics

Founded Year

2007

Location

Boulder, United States

Stage

Public

Total Funding

$14.5M in 3 rounds

Latest Funding Round

Post IPO, May 11, 2026, $*****

Investors

Longitude Capital & 3 more

Ranked

17^th among 2925 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

415 as on Aug 31, 2026

Similar Companies

Sana Biotechnology & 645 more

Exit Details

Public

View Viridian Therapeutics' full profile

Viridian Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VIRIDIAN THERAPEUTICS, INC.DE CIN: 1590750 , United States, Active	Dec 07, 2010	$50M - $100M (As on Dec 31, 2025)	94 (As on Dec 31, 2023)	-
VIRIDIAN THERAPEUTICS INC CIN: 844886842 , United States, Active	Dec 31, 1999	-	4 (As on Dec 31, 2020)	-
MIRAGEN THERAPEUTICS, INC. CIN: 471187261 , United States, Active	Dec 31, 1999	$1M - $10M (As on Dec 31, 2019)	139 (As on Dec 31, 2024)	-

Viridian Therapeutics got listed on Jun 20, 2014.

Click here to take a look at Viridian Therapeutics's IPO in detail

Viridian Therapeutics has raised a total funding of $14.5M over 3 rounds. Its first funding round was on Sep 10, 2010. Its latest funding round was a Post IPO round on May 11, 2026 for $*****. 1 investor participated in its latest round. Viridian Therapeutics has 4 institutional investors.

Here is the list of recent funding rounds of Viridian Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 11, 2026	1747988	Post IPO	8782818	5645895	9319492	5197134
Feb 03, 2015	5692412	Series A	9643981	2065196	4093737	2780723
Sep 10, 2010	6457052	Series A	3144982	2587017	1225813	8236749

Access funding benchmarks and valuations. Sign up today!

View details of Viridian Therapeutics's funding rounds and investors

The founders of Viridian Therapeutics is Vahe Bedian.

Here are the details of Viridian Therapeutics' key team members:

Vahe Bedian: Co-Founder of Viridian Therapeutics and founder of 1 other company.

View details of Viridian Therapeutics's Founder profiles and Board Members

Viridian Therapeutics' employee count trend

Viridian Therapeutics has 415 employees as of Aug 26. Here is Viridian Therapeutics's employee count trend over the years:

Employee count trend for Viridian Therapeutics

Uncover Viridian Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Viridian Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Viridian Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
17th	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100